 Connection
Kelly Faulk to Precursor Cell Lymphoblastic Leukemia-Lymphoma
This is a "connection" page, showing publications Kelly Faulk has written about Precursor Cell Lymphoblastic Leukemia-Lymphoma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.018 |
|
|
|
-
Murphy LA, Bradley ZK, Elozory AN, Gao D, Faulk KE. Universal Premedication Does Not Impact Transition to Short-acting Asparaginase or Incidence of Hypersensitivity to Pegylated Asparaginase: A Single-institution Experience. J Pediatr Hematol Oncol. 2025 07 01; 47(5):e181-e186.
Score: 0.705
-
Murphy L, Siegele B, Carstens B, Hartman L, Faulk K. A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy. Leuk Lymphoma. 2024 06; 65(6):843-847.
Score: 0.163
-
Cheung LC, Aya-Bonilla C, Cruickshank MN, Chiu SK, Kuek V, Anderson D, Chua GA, Singh S, Oommen J, Ferrari E, Hughes AM, Ford J, Kunold E, Hesselman MC, Post F, Faulk KE, Breese EH, Guest EM, Brown PA, Loh ML, Lock RB, Kees UR, Jafari R, Malinge S, Kotecha RS. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy. Leukemia. 2023 01; 37(1):61-71.
Score: 0.149
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|